Keyword: Insys Therapeutics
On the heels of the high-profile arrest of Insys' billionaire founder John Kapoor, the drugmaker has recorded a $150 million charge.
Federal agents arrested Insys founder John Kapoor and charged him with racketeering and other felonies.
New Jersey is targeting a doctor for his role in Insys' alleged cash-for-scripts scheme—and it aims to curb pharma's doctor payments, too.
Insys Therapeutics is the focus of a new congressional report detailing some former employees' sales techniques for powerful painkiller Subsys.
Representatives from several groups asked the FDA to consider pulling powerful opioids from the market.
Mylan has received a Department of Justice subpoena into its opioid business, according to a quarterly securities filing.
Beleaguered Insys faces yet another legal challenge with Anthem's decision to take the opioid drugmaker to court.
Two former Insys saleswomen have copped to charges that they took part in a kickback scheme designed to push sales of pain drug Subsys.
Embroiled in a web of allegations and investigations over Subsys marketing, Insys Therapeutics faces a new lawsuit.
A top Senate Democrat is throwing the weight of her office behind efforts to dig into opioid marketing practices.